Metavia Inc. (MTVA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
MetaVia Inc. (NASDAQ:MTVA) Short Interest Up 82.9% in February
MetaVia Inc. (NASDAQ: MTVA - Get Free Report) saw a significant growth in short interest in February. As of February 27th, there was short interest totaling 102,676 shares, a growth of 82.9% from the February 12th total of 56,146 shares. Based on an average daily volume of 131,429 shares, the short-interest ratio is currently 0.8 days.
Metavia Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 3 | $3.6 | $5.22 | $1.62 | 45% |
Metavia Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ASF Andrew S. Fein HC Wainwright & Co. | 246.91 | $2,000 | $429.63 | -$1,570.37 | -78.52% |
Metavia Inc. (MTVA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Metavia Inc. ever had a stock split?
Metavia Inc. Profile
| Biotechnology Industry | Healthcare Sector | Hyung Heon Kim CEO | NASDAQ (CM) Exchange | 64132R503 CUSIP |
| US Country | 9 Employees | - Last Dividend | 5 Dec 2025 Last Split | 5 Aug 2016 IPO Date |
Overview
MetaVia Inc., initially known as NeuroBo Pharmaceuticals, Inc., represents a pivotal force in the realm of clinical-stage biotechnology, primarily focusing on the innovation and commercialization of groundbreaking pharmaceuticals aimed at combating cardiometabolic diseases. With its headquarters situated in the vibrant scientific hub of Cambridge, Massachusetts, MetaVia stands at the forefront of advancing therapeutic interventions. After rebranding in November 2024, the company has intensified its endeavors in the development of novel therapeutic agents, underlining its commitment to addressing complex health challenges associated with metabolic and neurological disorders.
Products and Services
- DA-1241:
- DA-1726:
- ANA001:
- NB-01:
- NB-02:
- Gemcabene:
A cutting-edge G-Protein-Coupled Receptor 119 agonist, DA-1241, is currently undergoing a Phase 2a clinical trial targeting metabolic dysfunction-associated steatohepatitis (MASH). This therapeutic candidate has also successfully completed a Phase 1 clinical trial for the management of type 2 diabetes mellitus (T2DM). DA-1241 exemplifies MetaVia's strategic approach towards dual-purpose development, offering potential both as a standalone treatment and in combination with other therapies to optimize patient outcomes in metabolic diseases.
Embodying MetaVia's innovative drive, DA-1726 is a novel oxyntomodulin analogue that acts as a dual agonist for the GLP-1 receptor and glucagon receptor, focused on the treatment of obesity. Currently in preclinical development, DA-1726 aligns with the company's mission to tackle weight management issues at a molecular level, leveraging dual receptor activation to foster significant therapeutic advancements.
In the wake of the global health crisis induced by COVID-19, MetaVia promptly responded with ANA001, a proprietary oral niclosamide formulation designed for patients suffering from moderate manifestations of the virus. This initiative underscores the company's adaptable and responsive strategy in addressing emergent health concerns with agility and precision.
Targeting the debilitating condition of painful diabetic neuropathy, NB-01 represents MetaVia's commitment to improving quality of life for patients grappling with diabetes-related nerve pain. This therapeutic venture reflects the company's broader objective to alleviate the compounding challenges faced by individuals with diabetes.
Focused on cognitive impairment, NB-02 is a testament to MetaVia's dedication towards addressing neurological disorders with innovative therapeutic solutions. This development endeavor highlights the intersection of MetaVia's expertise in both metabolic and neurological domains, aiming to offer relief and hope to patients suffering from cognitive dysfunction.
As part of its comprehensive strategy to combat cardiometabolic diseases, Gemcabene emerges as a pivotal therapeutic candidate for the treatment of dyslipidemia. MetaVia's license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene solidifies the company's position in advancing lipid management therapies, aiming to reduce cardiovascular risk in affected populations.
